Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Realfiction Holding AB provides revised guidance for 2019

Realfiction Holding AB (“Realfiction”) reports that the timing of when its Sales Activities are expected to break-even has been pushed from any single month before the end of 2019 and into 2020 due to a temporary slow-down in the orders and revenue from its new Magic-as-a-Service concept.CEO Clas Dyrholm comments: “We are experiencing a temporary slow-down in the orders and revenue from our new Magic-as-a-Service concept. This is the case – in particular - in relation to our Exhibition vertical. We have seen that the sales generated via our partner-based go-to-market model within this

PowerCell delivers fuel cell system for tests in trucks at the German university RTWH Aachen

PowerCell Sweden AB has received an order for a MS-100 fuel cell system from the university RTWH Aachen for installation and tests in a medium-duty truck.The system will be used within the LiVe Project which aims at developing a cost-efficient electric drive-train solution for medium-duty distribution trucks. The LiVe Project is funded by the German Federal Ministry for the Environment, Nature Conservation, Construction and Nuclear Safety.The system, which is expected to be delivered during the fourth quarter 2019, will be installed in an 18 ton distribution truck to evaluate the use of

Mentice Q2 interim report 2019

Mentice AB (publ.) a leading supplier of high-technology solutions for simulation in the medical sector with focus on endovascular procedures, presents its interim report for second quarter 2019.   Comments from CEO First half year in line with our previous communications Net sales for the first half year increased to SEK 59.8 million (56.3) which is equivalent to a growth of 6,2%. We are confirming our short to medium term (next 3-5 years) financial target of a revenue growth of 30-40% per annum compounded, as stated in our first quarter interim report. For the current

2019 Q2 report, Period January-June for Panion Animal Health AB

Period April-June · Net sales: kSEK 0 (0). · Operating profit: kSEK -2 767 (-1 299). · Earnings per share: SEK -0,12 (-0,08). · Liquidity at the end of the period: kSEK 586 (15). Period January-June · Net sales: kSEK 0 (0). · Operating profit: kSEK -4 430 (-1 996). · Earnings per share: SEK -0,19 (-0,08). · Liquidity at the end of the period: kSEK 586 (15). Significant events after the end of the period:On July 10, 2019, it was announced that the shareholders of Panion Animal Health AB have accepted the offer from CombiGene AB with an acceptance rate

Saku Sipola starts as President and CEO of SRV Group Plc in September

SRV GROUP PLC             STOCK EXCHANGE RELEASE          29 AUGUST 2019    9.15 EET Saku Sipola starts as President and CEO of SRV Group Plc in September Appointed in June, M.Sc. (Tech) Saku Sipola will start in his role on 1 September 2019. SRV Group Plc’s Board of Directors appointed M.Sc. (Tech) Saku Sipola as President and CEO of SRV Group Plc in June. SRV announced that he will start in his new role at a later specified date, latest on 1 January 2020. Sipola joins SRV from SATO Corporation, where he has worked as the President and CEO since 2015. Prior to that Sipola, 50,

Borr Drilling Limited Announces Results for the Second Quarter 2019

Hamilton, Bermuda, August 29, 2019: Borr Drilling Limited (“Borr”, “Borr Drilling” or the “Company”) announces unaudited results for the three and six months ended June 30, 2019 Highlights in the second quarter 2019 · Operating revenues of $86.6 million, net loss of $103.2 million and Adjusted EBITDA of negative $4.9 million for the second quarter of 2019 · The results include a $31.5 million mark to market loss related to forward contracts the Company acquired in Rowan/Ensco (renamed Valaris PLC) in 2018. The share price of Valaris was as of June 30, 2019 $8.53. This relates to

Publication of interim financial report for January - June 2019

Nustay A/S (“Nustay”) hereby publishes financial report for the period of January - June 2019, showing a 40% increase in handled revenue in Q2 2019 compared to Q1 2019. The report is available as an attached document to this press release and on the Company’s website (www.nustay.com). Below is a summary of the report.Mathias Lundoe Nielsen, CEO of Nustay, comments: “Nustay experienced major growth in sales during Q1 and Q2 but we also faced a series of unforeseen challenges as part of this new chapter. The challenges were both related to integrations with our major marketing partners and

Anifrolumab Phase III trial meets primary endpoint

This announcement contains inside information 29 August 2019 07:00 BST Anifrolumab Phase III trial meets primary endpoint insystemic lupus erythematosus Positive top-line results from TULIP 2 trial demonstrate astatistically-significant and clinically-meaningful reduction indisease activity based on composite lupus assessment AstraZeneca today announced that the Phase III TULIP 2 trial for anifrolumab, a potential new medicine for the treatment of systemic lupus erythematosus (SLE), met its primary endpoint, achieving a statistically-significant and clinically-meaningful

AcadeMedia’s Year-end report July 2018 – June 2019

Fourth quarter (April – June 2019) · Net sales increased by 5.6 percent to SEK 3,162 million (2,993). Organic growth, including bolt-on acquisitions, was 5.3 percent. · Operating profit (EBIT) increased by 30.5 percent to SEK 218 million (167). Items affecting comparability in the period amounted to SEK -14 million (-40). Adjusted for items affecting comparability, operating profit was SEK 232 million (207). · Net profit for the period was SEK 148 million (111). · Cash flow from operating activities amounted to SEK 425 million (376). · The average number of children and

Plan for 510(k) submission specified - Q1 Interim Report: May-July 2019/2020

SEK thousands  Q1 19/20  Q1 18/19  May-April 18/19 Net sales  367  914  3,005 Operating profit (loss)  -6,097  -3,956  -21,718 Profit (loss) for the period  -6,068  -4,028  -21,556 Earnings per share, after dilution  -0.33  -0.23  -1.18  Significant events during the first quarter ·  Targeted new share issue for SEK 60 million to European and Swedish institutional investors and family offices ·  Positive study results from the EFECT study with DiviTum® published in the

IRRAS publishes Interim Report for the period January to June 2019

US sales started“During the second quarter, we reached a significant milestone by recording our first IRRAflow revenue in the United States (US). The US is the world´s largest market for neurosurgical procedures, and with the ongoing CE Mark recertification process, we have focused much of our team´s resources toward supporting a successful early market introduction in the US.” Kleanthis G. Xanthopoulos, Ph.D., President and CEO of IRRAS  Second quarter, April - June 2019 · Net revenue totaled SEK 1.1 million (0.1) · Operating loss (EBIT) amounted to SEK -40.7 million (-32.1)

­Sale of shares in Lime Technologies AB (publ)

Press release Stockholm 29 August 2019 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Monterro 1 AB (“Monterro”) has sold 1,500,000 shares in Lime Technologies AB (publ) ("Lime") through an accelerated bookbuilding to Swedish and international institutional investors at a price of SEK 110.00 per share (“the Placing”). Following the Placing, Monterro owns 2,534,555 shares in Lime corresponding to 19.08% of the total

Electrolux celebrates 100-year anniversary with action plan for sustainable living and funding for Food Foundation

Sweden’s Electrolux today introduced the Better Living Program, a plan to enable better and more sustainable living for consumers around the world through 2030. With bold targets focusing on better eating, better garment care and a better home environment, the initiative widens the scope of Electrolux commitment to sustainability and enables the company and its brands to contribute in a meaningful way on key global challenges.“At Electrolux we take a lot of pride in the way our appliances have helped shape hundreds of millions of people’s home lives for the better over the past 100 years.

Resurs Bank to become new payment solutions partner for Svensk Handel’s members

Svensk Handel (Swedish Trade Federation) has chosen Resurs as its partner for payment solution offers for its members for stores, e-commerce and omni-retail. The parties have jointly put together a concept that will enable Svensk Handel member companies to offer their customers rapid, secure and convenient shopping experiences, regardless of channel.Resurs Bank will now be the partner of Svensk Handel for its most recent payment solution offers to members. Resurs has extensive experience of helping retailers achieve higher average purchases and generate loyalty-creating sales through

Resurs Bank to become new payment solutions partner for Svensk Handel’s members

Svensk Handel (Swedish Trade Federation) has chosen Resurs as its partner for payment solution offers for its members for stores, e-commerce and omni-retail. The parties have jointly put together a concept that will enable Svensk Handel member companies to offer their customers rapid, secure and convenient shopping experiences, regardless of channel.Resurs Bank will now be the partner of Svensk Handel for its most recent payment solution offers to members. Resurs has extensive experience of helping retailers achieve higher average purchases and generate loyalty-creating sales through

Zenuity and CERN team up on fast machine learning for autonomous driving

Zenuity, the autonomous driving software company headquartered in Sweden, has become the first automotive company to team up with CERN, the European Organization for Nuclear Research, in the development of fast machine learning for autonomous drive cars.A fundamental challenge in the development of autonomous drive (AD) cars is the interpretation of the huge quantities of data generated by normal driving conditions, such as identifying pedestrians and vehicles with the sensors on the car, including cameras, lidar and radars.Addressing these issues is crucial for the development of safe

Interim Report January to June 2019 – continued strong net growth and successful new share issue

Second quarter 2019 · Operating income for the second quarter amounted to SEK 39,029 thousand (22,882), an increase of 71 percent · Net sales for the second quarter amounted to SEK 25,961 thousand (14,711), an increase of 76 percent · Earnings before depreciation (EBITDA) for the second quarter amounted to SEK -6,978 thousand (-18,453) · Result for the second quarter amounted to SEK -21,368 thousand (-28,712) · Earnings per share amounted to SEK -0.16 (-0.26) · Equity per share amounted to SEK 2.18 (2.26)January–June 2019 · Operating income for the period

Nordic Nanovector ASA: Invitation to R&D Day in Oslo and Webcast

Oslo, Norway, 29 August 2019 Nordic Nanovector ASA (OSE: NANO) announces that it will host a R&D Day in Oslo on Tuesday, 17 September 2019 from 9:30am to 12:30pm CEST. The programme will include presentations from three external experts and by Nordic Nanovector’s senior management team. An update on the median Duration of Response (mDoR) of Betalutin® treatment in the LYMRIT 37-01 trial will also be given during the day. Venue: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Auditorium To register to attend, please e-mail ir@nordicnanovector.com by 13

Karnov Group reports second quarter results

Steady growth & JUNO roll-outSecond quarter summary · Net sales up 4% to SEK 173 m (166), organic growth was 3%. · Adjusted EBITA increased by 8.8% to SEK 60 m (55) and adjusted EBITA margin improved by 1.4 percentage points to 34.7% (33.3). · EBITA declined by SEK 15 m to SEK 30 m (45) with EBITA margin of 17.6% (27.0%), due to SEK 19 m higher impact from items affecting comparability. · Operating profit (EBIT) declined to SEK -1 m (14). · Earnings per share SEK -0.45 (-0.18). · Adjusted operating cash flow amounted to SEK 18 m (23). · Preparations for the roll-out

Moberg Pharma AB Year-end report January - June 2019

EXECUTING ACCORDING TO PLAN WITH FOCUS ON MOB-015PERIOD (JAN-JUN 2019) · Net profit after tax SEK 558.8 million (6.7) · Total profit for the period SEK 499.4 million (27.3) · Diluted earnings per share SEK 31.35 (0.38) · Net revenue SEK 15.6 million (0.0) * · EBITDA SEK -3.0 million (-21.0) * · Operating profit (EBIT) SEK -4.2 million (-21.1) * · Cash and cash equivalents amounted to SEK 919.1 million (122.2) SECOND QUARTER (APR-JUN 2019) · Net profit after tax SEK -5.1 million (4.7) · Total profit for the period SEK -5.1 million (21.7) · Diluted

Xspray Pharma publishes Interim Report Q2, January – June 2019

August 29, 2019 ”We have previously shown that it is possible to manufacture small pilot quantities of amorphous material for clinical studies but now we have shown that the process works at commercial scale. We have ”cracked the code”, so to speak, and have taken a great step toward a finished product.” Per Andersson, CEO Xspray Pharma AB (publ)    Significant events during the second quarter 2019 · In June, Xspray announced the successful start of HyNap-Dasa production in the Company’s unique full-scale manufacturing facility in Italy · In June, Xspray was granted

Gradientech Granted Trademark for QuickMIC from United States Patent and Trademark Office

Uppsala, August 29, 2019. Gradientech AB today announces the trademark approval from the United States Patent and Trademark Office (USPTO) for QuickMIC®, its diagnostic system for ultrarapid antibiotic susceptibility testing. The registered trademark (Reg. No. 5817189) covers two classes for goods and services: Chemical and biological reagents for medical and veterinary use (IC 005) and diagnostic apparatus and instruments for analyzing cellular responses for medical and veterinary use (IC 010).Sara Thorslund, CEO of Gradientech, commented on QuickMIC's recent trademark status: "The

Systemair acquires distributor in Morocco

Press Release, August 29, 2019 Systemair AB (NASDAQ OMX Stockholm: SYSR) acquires distributor for Systemair's products in Morocco Systemair Maroc sells Systemair's products in Morocco and West Africa. The company had sales of approximately SEK 70 million in 2018 and has currently 27 employees. The sales company with office and warehouse in Casablanca has so far had a license agreement to act under the name Systemair. The acquisition represents 60 percent of the total shares in the company with an option to acquire the remaining shares within three years. "Morocco is a growth market

There are no items matching the current filter
There are no more items matching the current filter
Back to top